Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Oct. 10, 1997

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Oct. 8, 1997

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Oct. 7, 1997

Development of YM-46303 stopped

Oct. 2, 1997

Interstim approved for marketing in U.S.

Oct. 1, 1997

Alza to market IVAX urology products in U.S., Canada

Sep. 30, 1997

Bosentan evaluated in humans for preventing ciclosporin nephrotoxicity

Sep. 29, 1997

Synaptic focuses on dihydropyrimidinones for BPH

Sep. 29, 1997

Sildenafil continues to demonstrate efficacy in treating ED

Sep. 26, 1997

Design, synthesis and evaluation of SNAP-5582 derivatives for BPH

Sep. 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...